
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : APC-148,Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Venus Remedies
Deal Size : Undisclosed
Deal Type : Collaboration
AdjuTec, Venus Remedies initiate research collaboration to evaluate APC-148 against AMR
Details : Venus Remedies will test APC-148, a selective inhibitor targeting bacterial MBL enzymes, in combination with various antibiotics against multidrug-resistant bacterial strains.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
March 26, 2025
Lead Product(s) : APC-148,Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Venus Remedies
Deal Size : Undisclosed
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : APC148
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : CTC Clinical Trial Consultants
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : APC148 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 11, 2024
Lead Product(s) : APC148
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : CTC Clinical Trial Consultants
Deal Size : Inapplicable
Deal Type : Inapplicable
